Stay updated on Senolytic Therapy in Alzheimer's Clinical Trial
Sign up to get notified when there's something new on the Senolytic Therapy in Alzheimer's Clinical Trial page.

Latest updates to the Senolytic Therapy in Alzheimer's Clinical Trial page
- Check4 days agoChange DetectedThe record describes a Phase II randomized, placebo-controlled study of dasatinib and quercetin for older adults with early Alzheimer’s disease or amnestic mild cognitive impairment. It includes the study’s eligibility criteria, treatment schedule, locations, and outcome measures.SummaryDifference53%

- Check11 days agoChange DetectedThe footer’s site revision identifier changes from v3.7.2 to v3.8.0, while the study record continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check25 days agoChange DetectedA banner announces an NIH terminology transition from “Artificial Intelligence” to “Super Intelligence,” and the site revision advances from v3.7.1 to v3.7.2. The study record itself remains inaccessible behind a 403 error.SummaryDifference1%

- Check39 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check53 days agoChange DetectedThe page now presents a 403 Forbidden error instead of the study record content, signaling an access restriction or load failure that prevents viewing the study details.SummaryDifference19%

- Check60 days agoChange DetectedRevision updated from v3.6.6 to v3.7.0, indicating a software/content update to the page. This update does not change the reported study details, eligibility criteria, or other user-facing information.SummaryDifference0.1%

Stay in the know with updates to Senolytic Therapy in Alzheimer's Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Senolytic Therapy in Alzheimer's Clinical Trial page.